688075 XD安旭生物
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.6523.7292.68875.84743.212
总资产报酬率 ROA (%)0.5863.3272.22259.51633.712
投入资产回报率 ROIC (%)0.6303.5732.52970.57740.400

边际利润分析
销售毛利率 (%)42.31939.10242.29874.78265.445
营业利润率 (%)30.20238.39233.27357.23254.432
息税前利润/营业总收入 (%)32.07531.85914.47948.42655.856
净利润/营业总收入 (%)29.68635.55328.00549.37146.469

收益指标分析
经营活动净收益/利润总额(%)-18.47418.31542.170119.289101.392
价值变动净收益/利润总额(%)113.01386.23259.3151.3921.381
营业外收支净额/利润总额(%)0.0531.451-16.457-0.265-0.052

偿债能力分析
流动比率 (X)9.73410.0358.7884.5694.533
速动比率 (X)9.4469.7268.4284.4244.162
资产负债率 (%)10.4859.87211.81122.04420.544
带息债务/全部投入资本 (%)1.4191.5772.4893.7826.720
股东权益/带息债务 (%)6,797.5116,128.4533,815.5472,465.1861,379.401
股东权益/负债合计 (%)854.289913.676747.187353.842386.752
利息保障倍数 (X)17.273-4.489-1.027-5.59638.454

营运能力分析
应收账款周转天数 (天)190.155133.025155.98222.02986.606
存货周转天数 (天)196.708188.213244.44251.010121.161